在初级保健中减少多领域痴呆风险是可行的:一项概念验证研究
Stephanie Van Asbroeck1, Sebastian Köhler1, Sophie C P M Wimmers1
1Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Mental Health and Neuroscience (MHeNs) Research Institute, Maastricht University, Maastricht, the Netherlands.
Journal of Alzheimer's disease : JAD
|May 17, 2024
概括
将痴呆风险降低纳入初级保健是可行的,智能手机应用程序可以增强知识. 这种方法支持减少痴呆风险的公共卫生目标.
科学领域:
- 公共卫生 公共卫生
- 老年学是一门学科.
- 数字健康数字健康
背景情况:
- 降低痴呆风险是一个关键的公共卫生问题.
- 对于日常护理的可访问干预措施是有限的.
研究的目的:
- 评估将痴呆风险降低策略整合到初级保健中的可行性.
- 在这种情况下,评估智能手机应用程序 ("MyBraincoach") 的附加值.
主要方法:
- 一个集群随机试验,涉及188名参与者 (40-60岁) 具有可修改的痴呆风险因素.
- 实践被随机选择,提供单独的风险降低咨询或使用"MyBraincoach"应用程序.
- 三个月后通过问卷和采访评估可行性,主要结果是"大脑健康的生活方式" (LIBRA) 评分的变化.
主要成果:
- 干预得到了好评,72.0%的人认为咨询信息丰富,69.2%的人认为应用程序有用.
- 在两组中,LIBRA分数,地中海饮食坚持和BMI均有较低的退学率 (6.9%) 和相似的改善.
- 增加了对降低痴呆风险的知识,特别是在APP组.
结论:
- 将痴呆风险降低整合到初级保健中,加上智能手机应用程序,是一个可行的策略.
- 需要进一步的研究来证实这种综合方法的 (成本) 有效性.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.痴呆症 痴呆症是一种痴呆症.健康行为健康行为生活方式 生活方式预防和控制 预防和控制初级医疗保健是一项主要的医疗保健服务.有关风险因素的风险因素.远程医疗远程医疗更多相关视频
07:42Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
2.9K
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.3K
相关概念视频
Dementia
112
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
112
Alzheimer's Disease: Overview
467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
